GlassScriptPhysician profile
Cherish C Holt
NPI 1659703817
$19,570.67
in general payments reported to CMS, 2019-2025
49 companies · $3,417 in 2025
The $3,417 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,700 · 2022: $3,824 · 2023: $4,550 · 2024: $4,079 · 2025: $3,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,003.52 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,075.18 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $2,615.48 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $2,019.66 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $1,311.21 | 2021-2025 | Evenity, Repatha, Prolia |
| Cequr Corporation | $1,271.54 | 2023-2025 | Cequr Simplicity |
| Corcept Therapeutics | $875.29 | 2021-2025 | Korlym |
| Beta Bionics, INC. | $849.38 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Xeris Pharmaceuticals, INC. | $833.90 | 2021-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $611.52 | 2021-2025 | Jardiance, Synjardy |
| Dexcom, INC. | $551.46 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Insulet Corporation | $505.65 | 2021-2025 | Omnipod |
| Ibsa Pharma INC. | $482.94 | 2021-2025 | Tirosint, Tirosint, Licart |
| Sanofi-Aventis U.S. LLC | $480.33 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $450.01 | 2021-2024 | Farxiga |
| Mannkind Corporation | $414.64 | 2021-2025 | Afrezza |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherish Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.